slides · global inventory
Analyze Data
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 58,039
Current window 31,231-31,260
Pages 1,935
Rows per page 30
Slide function
31,231-31,260 of 58,039
55
The chart highlights the significant deviation from the historical trend starting in 2020.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Satisfaction1 hit
61
The chart highlights a clear preference for digital interaction across most tasks, while acknowledging the continued role of the physical forecourt.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations 1 hit
62
Data from Auto Trader Car Buyers Tracker, July 2022, n=2,002.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations 1 hit
78
Auto Trader Group | Investor Day Presentation Deck | 100 slidesAuto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations 1 hit
82
The slide uses a grouped bar chart to contrast pre-pandemic and current performance metrics.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
89
Uses a simple arithmetic equation structure to illustrate margin buildup.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations 1 hit
92
The slide uses a line chart for adoption and a bar chart for retention to illustrate product stickiness.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
96
The slide uses a tabular structure to explain the decomposition of financial reporting segments.Auto Trader Group | Investor Day Presentation Deck | 100 slides · Auto Trader
Conference presentation Investor relations Beat · Action1 hit
12
Standard clinical trial subject disposition flow chart.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
13
The table includes demographic, metabolic, inflammatory, and fibrosis markers.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
15
The data shows a statistically significant improvement in the high-dose group at Week 24.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Cost Of Inaction1 hit
16
The slide shows clinical trial data comparing two biomarkers for fibrosis treatment efficacy.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
17
Clinical trial data showing statistically significant reductions in ALT for AXA1125 groups compared to placebo.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
18
Shows statistically significant effects at week 12 for AXA1125 treatment arms.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
19
Data shows proportions of subjects meeting specific thresholds associated with histologic improvements in NASH.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
26
The slide uses bar charts to show dose-dependent increases in metabolic markers and a table to show pathway enrichment scores.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
27
The slide uses a pathway diagram and a bar chart to demonstrate the mechanism of action of AXA1125 in a Primary Human Hepatocyte (PHH) Lipotoxicity Model.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
28
Includes statistical significance markers (*, **, ***) and experimental methodology in the footer.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
29
The slide presents preclinical data from primary human hepatic stellate cells.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
32
Includes a map-based visualization of regional prevalence and a grouped bar chart for age/sex demographics.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
33
Uses a before-after-bridge framework to highlight the growth in Fibrosis stage 2-4 prevalence.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
34
Data source: Harrison SA et al. J Hepatol. 2021;S0168-8278:00176-8.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
39
The slide includes a prominent callout box summarizing the clinical significance of the baseline data.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
43
The slide compares three groups (Placebo, AXA1125 22.6 BID, AXA1125 33.9 BID) across two time points (Week 12 and Week 24).Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
45
The slide title mentions week 12, but the charts explicitly label week 24. This is a common discrepancy in clinical trial decks where data is presented across multiple time points.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
46
N=931. Data presented for Placebo, OCA 10mg, and OCA 25mg cohorts.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
47
The slide presents longitudinal data from the REGENERATE trial, specifically focusing on FIB-4 scores as a non-invasive test (NIT) for fibrosis.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
48
P-values are calculated using Cochran-Mantel Haenszel test vs placebo.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
50
The slide uses a forest plot to visualize odds ratios and confidence intervals for clinical predictors.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit
51
The slide uses a dark sidebar for context and a white main area for data presentation. It includes a citation at the bottom.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations 1 hit